Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial (vol 54, pg 279, 2017)

In Table II, P value in first row (against 'continuing apnea' at 1-3 d of therapy) should be 0.05 in place of 0.03; and in second row (against 'continuing apnea' at 4-7 d of therapy), P value should be 0.03 in place of 0.05. In Fig. 1, the number in the frame Neonates completed treatment and follow-up in the Caffeine group should be read as 77 in place of 79; and in the Aminophylline group, it should be 79 in place of 77.